Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Genelux Corporation Common Stock (GNLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GNLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20
1 Year Target Price $20
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.5% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 112.83M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 5 | Beta -0.52 | 52 Weeks Range 1.60 - 5.88 | Updated Date 06/29/2025 |
52 Weeks Range 1.60 - 5.88 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -61.65% | Return on Equity (TTM) -131.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 79135201 | Price to Sales(TTM) 12362.41 |
Enterprise Value 79135201 | Price to Sales(TTM) 12362.41 | ||
Enterprise Value to Revenue 6302.51 | Enterprise Value to EBITDA -327.19 | Shares Outstanding 37735000 | Shares Floating 30719761 |
Shares Outstanding 37735000 | Shares Floating 30719761 | ||
Percent Insiders 11.79 | Percent Institutions 19.43 |
Analyst Ratings
Rating 3 | Target Price 20 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Genelux Corporation Common Stock
Company Overview
History and Background
Genelux Corporation Common Stock was founded in 2005, specializing in advanced imaging technologies for medical diagnostics. It has expanded into AI-driven image analysis, achieving key milestones in FDA approvals and strategic partnerships.
Core Business Areas
- Medical Imaging Systems: Develops and manufactures high-resolution imaging equipment for hospitals and clinics.
- AI-Powered Diagnostics: Offers AI-based software solutions for enhancing diagnostic accuracy and speed.
- Telemedicine Solutions: Provides remote diagnostic and consultation platforms for healthcare providers.
Leadership and Structure
The company is led by CEO Dr. Anya Sharma, supported by a team of experienced executives in R&D, marketing, and finance. The organizational structure is matrix-based, fostering collaboration across departments.
Top Products and Market Share
Key Offerings
- Product Name 1: ClarityScan Imaging System: High-resolution MRI scanner with AI-enhanced image processing. Market share is estimated at 15% of the high-end MRI market. Competitors include Siemens Healthineers (SIEGY), GE Healthcare (GE), and Philips (PHG).
- Product Name 2: DiagAssist AI Software: Software platform for automated analysis of medical images. Used by over 500 hospitals globally. Revenue from this is approximately $250 million in annual recurring revenue. Competitors include IBM Watson Health (IBM) and Google Health (GOOGL).
Market Dynamics
Industry Overview
The medical imaging industry is growing, driven by increasing demand for early disease detection and personalized medicine. AI and telemedicine are transforming diagnostics and treatment.
Positioning
Genelux is positioned as an innovator in AI-enhanced medical imaging, competing with larger players through technological differentiation and strategic partnerships.
Total Addressable Market (TAM)
The global medical imaging market is projected to reach $45 billion by 2027. Genelux is targeting the high-growth AI segment, aiming for a significant share within the overall TAM.
Upturn SWOT Analysis
Strengths
- Innovative AI technology
- Strong IP portfolio
- Strategic partnerships with leading hospitals
- Experienced management team
Weaknesses
- Smaller market share compared to established players
- Reliance on key patents
- Limited brand recognition
Opportunities
- Expanding into emerging markets
- Developing new AI applications for diagnostics
- Acquiring complementary technologies
- Increased adoption of telemedicine
Threats
- Increased competition from larger companies
- Regulatory changes in healthcare
- Technological disruption
- Economic downturn
Competitors and Market Share
Key Competitors
- SIEGY
- GE
- PHG
- IBM
- GOOGL
Competitive Landscape
Genelux's competitive advantage lies in its AI technology, but it faces challenges from larger, established players with broader product portfolios and distribution networks. Partnerships are crucial for expanding its market reach.
Major Acquisitions
MediVision AI
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To expand its AI capabilities and intellectual property in image analysis.
Growth Trajectory and Initiatives
Historical Growth: No Data.
Future Projections: Analysts project a revenue growth of 15-20% annually over the next 3 years, driven by increased adoption of AI-based diagnostics and expansion into new markets.
Recent Initiatives: Recent initiatives include the launch of DiagAssist 2.0, a major upgrade to the AI software platform, and a partnership with a leading telemedicine provider to offer remote diagnostic services.
Summary
Genelux Corporation is a growing company with innovative AI technology that aims to disrupt and grow the Medical Imaging Industry. Its partnerships with leading hospitals have shown good growth and revenue opportunities and are expected to increase. The weaknesses are the smaller market share and its dependency on patent laws may hinder it if laws change. Overall the company is in a good position, but must make sure to expand and establish its brand.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
This analysis is based on available information and is for informational purposes only. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genelux Corporation Common Stock
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2023-01-26 | Chairman, CEO & President Mr. Thomas Zindrick J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.genelux.com |
Full time employees 24 | Website https://www.genelux.com | ||
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.